| Bretylium | Approved | SLC6A2 | Norepinephrine transporter substrate |
| Clidinium | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Demecarium | Approved | ACHE | Acetylcholinesterase inhibitor |
| Hexocyclium | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Lithium carbonate | Approved | IMPA1, GSK3A, GSK3B | Inositol-1(or 4)-monophosphatase 1 inhibitor |
| Potassium iodide | Approved | — | Unknown |
| Potassium perchlorate | Approved | — | — |
| Potassium phosphate, monobasic | Approved | — | — |
| Selenium sulfide | Approved | — | Unknown |
| Sodium bicarbonate | Approved | — | — |
| Sodium gluconate | Approved | — | — |
| Sodium iodide | Approved | — | — |
| Sodium monofluorophosphate | Approved | — | — |
| Sodium phosphate, monobasic | Approved | — | — |
| Sodium polystyrene sulfonate | Approved | Potassium | Potassium sequestering agent |
| Sodium zirconium cyclosilicate | Approved | Potassium | Potassium chelating agent |
| Technetium tc 99M sulfur colloid | Approved | — | Diagnostic agent |
| Technetium tc 99M tilmanocept | Approved | — | Diagnostic |
| Technetium TC-99M labeled carbon | Approved | — | — |
| Trospium | Approved | CHRM3, CHRM2 | Muscarinic acetylcholine receptor M3 antagonist |
| Helium | Phase 3 | — | — |
| Lithium | Phase 3 | — | — |
| Sodium ferric gluconate complex | Phase 3 | — | Supplement |
| Gallium nitrate | Phase 2 | Ribonucleoside-diphosphate reductase RR1, Hydroxyapatite | Ribonucleoside-diphosphate reductase RR1 inhibitor |
| Potassium gluconate | Phase 1 | — | — |
| Potassium bicarbonate | Early phase 1 | — | — |
| Barium sulfate | — | — | Diagnostic agent |
| Hexafluorenium | — | ACHE | Acetylcholinesterase inhibitor |
| Pentolinium | — | CHRNA3, CHRNB4 | Neuronal acetylcholine receptor; alpha3/beta4 antagonist |
| Technetium tc 99M depreotide | — | — | Diagnostic agent |
| Aluminium oxide | Approved | — | — |
| Gallium oxodotreotide | Approved | — | Diagnostic agent |
| Lithium citrate anhydrous | Approved | IMPA1, GSK3A, GSK3B | Inositol-1(or 4)-monophosphatase 1 inhibitor |
| Lutetium chloride | Approved | — | Diagnostic agent |
| Lutetium oxodotreotide | Approved | Somatostatin receptor | Somatostatin receptor binding agent |
| Magnesium carbonate | Approved | — | Neutralises acid |
| Magnesium chloride anhydrous | Approved | — | — |
| Magnesium citrate | Approved | — | Osmotic laxative |
| Magnesium hydroxide | Approved | — | Saline laxative |
| Magnesium oxide | Approved | — | — |
| Magnesium sulfate anhydrous | Approved | — | Unknown |
| Pinaverium | Approved | — | — |
| Potassium chloride | Approved | — | Supplement |
| Potassium citrate anhydrous | Approved | — | — |
| Prajmalium | Approved | — | — |
| Radium dichloride | Approved | — | Radiotherapy agent |
| Rubidium chloride | Approved | — | — |
| Samarium lexidronam pentasodium | Approved | — | Unknown |
| Sodium acetate | Approved | — | — |
| Sodium ascorbate | Approved | — | — |
| Sodium chloride | Approved | — | — |
| Sodium citrate | Approved | — | — |
| Sodium feredetate | Approved | — | Supplement |
| Sodium fluoride | Approved | — | — |
| Sodium phosphate, dibasic, anhydrous | Approved | — | Radiopharmaceutical |
| Sodium salicylate | Approved | — | — |
| Sodium sulfate anhydrous | Approved | — | Laxative |
| Strontium chloride | Approved | — | Unknown |
| Technetium pentetate | Approved | — | Diagnostic agent |
| Technetium sestamibi | Approved | — | Diagnostic agent |
| Titanium dioxide | Approved | — | — |
| Yttrium chloride | Approved | — | Diagnostic agent |
| Yttrium y 90 ibritumomab tiuxetan | Approved | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Bifidobacterium spp. | Phase 3 | — | Probiotic |
| Chromium | Phase 3 | — | — |
| Dequalinium | Phase 3 | — | Unknown |
| Enisamium | Phase 3 | — | — |
| Hafnium oxide | Phase 3 | — | — |
| Indium in 111 ibritumomab tiuxetan | Phase 3 | — | — |
| Magnesium | Phase 3 | — | — |
| Opium | Phase 3 | — | — |
| Potassium | Phase 3 | — | — |
| Potassium nitrate | Phase 3 | — | — |
| Radium | Phase 3 | — | — |
| Samarium | Phase 3 | — | — |
| Selenium | Phase 3 | — | — |
| Sodium alginate | Phase 3 | — | — |
| Sodium dichloroacetate | Phase 3 | Pyruvate dehydrogenase kinase | Pyruvate dehydrogenase kinase inhibitor |
| Sodium lactate | Phase 3 | — | — |
| Sodium lauryl sulfate | Phase 3 | — | — |
| Strontium | Phase 3 | — | — |
| Yttrium y 90 clivatuzumab tetraxetan | Phase 3 | MUC5AC | Mucin-5AC binding agent |
| Alagebrium | Phase 2 | — | — |
| Albitiazolium | Phase 2 | — | — |
| Amezinium | Phase 2 | — | — |
| Cetylpyridinium | Phase 2 | — | Unknown |
| Gallium citrate | Phase 2 | — | — |
| Lutetium (LU177) rosopatamab tetraxetan | Phase 2 | — | — |
| Lutetium lu 177 zadavotide guraxetan | Phase 2 | — | — |
| Lutetium rofapitidexetan | Phase 2 | — | — |
| Nolpitantium | Phase 2 | — | — |
| Potassium hydroxide | Phase 2 | — | — |
| Potassium magnesium citrate (4:1:2) | Phase 2 | — | — |
| Potassium phosphate, dibasic | Phase 2 | — | — |
| Prifinium | Phase 2 | — | — |
| Propagermanium | Phase 2 | — | — |
| Psyllium husk | Phase 2 | — | — |
| Repagermanium | Phase 2 | — | — |
| Sodium benzoate | Phase 2 | — | Unknown |
| Sodium butyrate | Phase 2 | — | — |
| Sodium ferrous citrate | Phase 2 | — | — |
| Sodium nitrate | Phase 2 | — | — |
| Sodium phenylacetate | Phase 2 | Glutamine | Glutamine sequestering agent |
| Sodium propionate | Phase 2 | — | — |
| Sodium succinate | Phase 2 | — | — |
| Sodium tungstate | Phase 2 | — | — |
| Timepidium | Phase 2 | — | — |
| Yttrium | Phase 2 | — | — |
| Yttrium y 90 epratuzumab tetraxetan | Phase 2 | CD22 | CD22 inhibitor |
| Actinium dotatate | Phase 1 | — | — |
| Cesium | Phase 1 | — | — |
| Chromium picolinate | Phase 1 | — | — |
| Exeporfinium | Phase 1 | — | — |
| Lutetium (LU177) lilotomab satetraxetan | Phase 1 | — | — |
| Lutetium LU177 edotreotide | Phase 1 | — | — |
| Lutetium PSMA-R2 | Phase 1 | — | — |
| Magnesium stearate | Phase 1 | — | — |
| Neotetrazolium | Phase 1 | — | — |
| Potassium sodium hydrogen citrate anhydrous | Phase 1 | — | — |
| Pudexacianinium | Phase 1 | — | — |
| Pyrvinium | Phase 1 | — | Unknown |
| Rhenium RE-186 obisbemeda | Phase 1 | — | — |
| Sodium pentaborate | Phase 1 | — | — |
| Sodium sulfide | Phase 1 | — | — |
| Technetium mebrofenin | Phase 1 | — | — |
| Utenpanium | Phase 1 | — | — |
| Potassium phosphate, unspecified form | Early phase 1 | — | — |
| Technetium | Early phase 1 | — | — |
| Aluminium nicotinate | — | — | — |
| Bephenium | — | — | — |
| Bephenium hydroxynaphthoate | — | — | Unknown |
| Cerium oxalate | — | — | — |
| Fenpiverinium | — | — | — |
| Indium chloride | — | — | Diagnostic agent |
| Indium in 111 capromab pendetide | — | — | Diagnostic agent |
| Indium oxyquinoline | — | — | Diagnostic agent |
| Indium pentetreotide | — | — | Diagnostic agent |
| Lapyrium | — | — | Unknown |
| Magnesium peroxide | — | — | — |
| Potassium salicylate | — | — | — |
| Potassium sulfate | — | — | Unknown |
| Rimazolium | — | — | — |
| Rubidium | — | — | Diagnostic agent |
| Sodium chromate | — | — | Radiopharmaceutical |
| Sodium pertechnetate | — | — | Diagnostic agent |
| Sodium tartrate | — | — | — |
| Technetium (99MTC) apcitide | — | — | Diagnostic agent |
| Technetium pyrophosphate | — | — | Diagnostic agent |
| Technetium succimer | — | A2M | Alpha-2-macroglobulin binding agent |
| Technetium tc 99M albumin aggregated | — | — | Diagnostic agent |
| Technetium tc 99M arcitumomab | — | — | Diagnostic agent |
| Technetium tc 99M fanolesomab | — | — | Diagnostic |
| Technetium tc 99M nofetumomab merpentan | — | — | Diagnostic agent |
| Technetium tc 99M red blood cells | — | — | Diagnostic agent |
| Technetium TC-99M trofolastat chloride | — | — | Diagnostic |
| Thiazinamium | — | — | — |
| Ytterbium pentetate | — | Radioactive metals | Radioactive metals chelating agent |
| Yttrium y 90 capromab pendetide | — | FOLH1 | Glutamate carboxypeptidase II binding agent |
| Yttrium y 90 epratuzumab | — | CD22 | CD22 binding agent |
| Yttrium y 90 labetuzumab | — | CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent |
| Yttrium y 90 tacatuzumab tetraxetan | — | AFP | Alpha-fetoprotein binding agent |
| Atracurium | Approved | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Cisatracurium | Phase 3 | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Mivacurium | Phase 2 | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Doxacurium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Glycopyrronium | Approved | CHRM3, CHRM1, Muscarinic acetylcholine receptor | Muscarinic acetylcholine receptor M3 antagonist |
| Isavuconazonium | Approved | Lanosterol 14-alpha demethylase | Lanosterol 14-alpha demethylase inhibitor |
| Oxyphenonium | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Sofpironium | Approved | Muscarinic acetylcholine receptor | Muscarinic acetylcholine receptor inhibitor |
| Rocuronium | Phase 3 | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Edrophonium | Phase 1 | ACHE | Acetylcholinesterase inhibitor |
| Ambenonium | — | ACHE | Acetylcholinesterase inhibitor |
| Decamethonium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor partial agonist |
| Pancuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Pipecuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Rapacuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Vecuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Emepronium | Approved | — | — |
| Diammonium glycyrrhizinate | Phase 3 | — | — |
| Otilonium | Phase 3 | — | — |
| Suxamethonium | Phase 3 | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor agonist |
| Benzoxonium | Phase 2 | — | — |
| Bibenzonium | Phase 2 | — | — |
| Denatonium | Phase 2 | — | — |
| Meldonium | Phase 2 | — | — |
| Sepantronium | Phase 2 | — | — |
| Tibezonium | Phase 2 | — | — |
| Tiemonium | Phase 2 | — | — |
| Zirconium (89ZR) girentuximab senvedoxam | Phase 2 | — | — |
| Ammonium tetrathiomolybdate | Phase 1 | — | — |
| Benzalkonium | Phase 1 | Cell membrane | Cell membrane disrupting agent |
| Tolonium | Phase 1 | — | — |
| Zirconium ZR-89-desferrioxamine-IAB22M2C | Phase 1 | — | — |
| Alcuronium | — | CHRM2 | Muscarinic acetylcholine receptor M2 positive allosteric modulator |
| Ambutonium | — | — | Unknown |
| Ammonium lactate | — | — | Unknown |
| Benzilonium | — | — | — |
| Bevonium | — | — | — |
| Fentonium | — | — | — |
| Methiosulfonium | — | — | — |